Citations

Mayo Clinic

Showing 10 of 108551 citations.

From Case Reports to Molecular Insight: Examining the Outcomes and Underlying Mechanisms of Squamous Cell Carcinoma in Breast Implant Patients—A Systematic Review
Camicia, Alexandra, Foppiani, Jose , Raška, Otakar , Alvarez, Angelica Hernandez , Schuster, Kirsten A. , Wan, Rou , Neradová, Sylva, Lin, Gavin J., Lee, Theodore C., Lin, Samuel J. , Hernandez Alvarez, Angelica , Wan, Rou , Lee, Daniela , Taritsa, Iulianna C. , Molitor, Martin , Zikán, Michal

International Journal of Molecular Sciences | March 1, 2024 | Volume: 25 | Issue: 5 | Pages: 2872

10.3390/ijms25052872 | PMID 38474119 Get It

There is extensive coverage in the existing literature on implant-associated lymphomas like anaplastic large-cell lymphoma, but breast implant-associated squamous cell carcinoma (BIA-SCC) has received limited scholarly attention since its first case in 1992. Thus, this study aims to conduct a qualitative synthesis focused on the underexplored association between breast implants and BIA-SCC. A systematic review was conducted utilizing the PubMed, Web of Science, and Cochrane databases to identify all currently reported cases of BIA-SCC. Additionally, a literature review was performed to identify potential biochemical mechanisms that could lead to BIA-SCC. Studies were vetted for quality using the NIH quality assessment tool. From an initial pool of 246 papers, 11 met the quality criteria for inclusion, examining a total of 14 patients aged between 40 and 81 years. BIA-SCC was found in a diverse range of implants, including those with smooth and textured surfaces, as well as those filled with saline and silicone. The condition notably manifested a proclivity for aggressive clinical progression, as evidenced by a mortality rate approximating 21.4% within a post-diagnostic interval of six months. Our literature review reveals that chronic inflammation, driven by various external factors such as pathogens and implants, can initiate carcinogenesis through epigenetic modifications and immune system alterations. This includes effects from exosomes and macrophage polarization, showcasing potential pathways for the pathogenesis of BIA-SCC. The study highlights the pressing need for further investigation into BIA-SCC, a subject hitherto inadequately addressed in the academic sphere. This necessitates the urgency for early screening and intervention to improve postoperative outcomes. While the review is confined by its reliance on case reports and series, it serves as a valuable reference for future research endeavors.
In Reply to Serum Free Light Chain and Drift: Calibrator Adjustment Needed?
Murray, David , Murray, David L

The Journal of Applied Laboratory Medicine | March 1, 2024 | Volume: 9 | Issue: 2 | Pages: 396-398

10.1093/jalm/jfad121 | PMID 38424718 Get It

A tension offloading patch mitigates dermal fibrosis induced by pro-fibrotic skin injections
Wan, Derrick C. , Talbott, Heather E. , Griffin, Michelle , Mascharak, Shamik , Parker, Jennifer , Kuhnert, Maxwell M. , Guo, Jason , Deleon, Nestor Diaz, Lavin, Christopher V. , Abbas, Darren , Morgan, Annah , Valencia, C. Alexander , Cotterell, Asha C., Talbott, Heather E , Abbas, Darren , Guardino, Nicholas , Longaker, Michael T , desJardins-Park, Heather Elizabeth, Parker, Jennifer, Guo, Jason L. , Deleon, Nestor M. Diaz , Longaker, Michael T.

No container title available | March 1, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3915097/v1 | PMID 38464040 Get It

Abstract Skin fibrosis is a clinical problem with devastating impacts but limited treatment options. In the setting of diabetes, insulin administration often causes local dermal fibrosis, leading to a range of clinical sequelae including impeded insulin absorption. Mechanical forces are important drivers of fibrosis and, clinically, physical tension offloading at the skin level using an elastomeric patch significantly reduces wound scarring. However, it is not known whether tension offloading could similarly prevent skin fibrosis in the setting of pro-fibrotic injections. Here, we develop a porcine model using repeated local injections of bleomycin to recapitulate key features of insulin-induced skin fibrosis. Using histologic, tissue ultrastructural, and biomechanical analyses, we show that application of a tension-offloading patch both prevents and rescues existing skin fibrosis from bleomycin injections. By applying single-cell transcriptomic analysis, we find that the fibrotic response to bleomycin involves shifts in myeloid cell dynamics from favoring putatively pro-regenerative to pro-fibrotic myeloid subtypes; in a mechanomodulatory in vitro platform, we show that these shifts are mechanically driven and reversed by exogenous IL4. Finally, using a human foreskin xenograft model, we show that IL4 treatment mitigates bleomycin-induced dermal fibrosis. Overall, this study highlights that skin tension offloading, using an FDA cleared, commercially available patch, could have significant potential clinical benefit for the millions of patients dependent on insulin.
HLA-DQB1*05 subtypes and not DRB1*10:01 mediates risk in anti-IgLON5 disease
Yogeshwar, Selina , Muñiz‐Castrillo, Sergio , Sabater, Lídia , Peris-Sempere, Vicente, Mallajosyula, Vamsee , Guo, Luo, Yan, Han , Lin, Ling , Bueno, Flavia Fagundes, Ji, Xuhuai , Picard, Géraldine , Pinto, Anne Laurie, Heidbreder, Anna , Dalmau, Josep , Santamaría, Joan , Iranzo, Alex, Schreiner, Bettina , Giannoccaro, Maria Pia , Kimura, Akio , Ono, Yoya , Bonello, Michael , Nigro, Pasquale , Prüß, Harald , McKeon, Andrew, Irani, Sarosh R. , Gaig, Carles , Mignot, Emmanuel , Luo, Guo , Yogeshwar, Selina M , Höftberger, Romana , Iranzo, Alex , Dinoto, Alessandro , Irani, Sarosh R , Honnorat, Jérôme , Finke, Carsten , Mignot, Emmanuel , Muñiz-Castrillo, Sergio , Dalmau, Josep O , Heidbreder, Anna , Luo, Guo, Yu, Eric , Zhang, Jing , Rogemond, Véronique , Graus, Francesc , Liguori, Rocco , Shimohata, Takayoshi , Binks, Sophie , Mariotto, Sara , Dinoto, Alessandro , Hartmann, Christian Johannes , Tambasco, Nicola , McKeon, Andrew , Davis, Mark M. , Honnorat, Jérôme

Brain | March 1, 2024 | Volume: 147 | Issue: 7 | Pages: 2579-2592

10.1093/brain/awae048 | PMID 38425314 Get It

Abstract Anti-IgLON5 disease is a rare and likely underdiagnosed subtype of autoimmune encephalitis. The disease displays a heterogeneous phenotype that includes sleep, movement and bulbar-associated dysfunction. The presence of IgLON5-antibodies in CSF/serum, together with a strong association with HLA-DRB1*10:01∼DQB1*05:01, supports an autoimmune basis. In this study, a multicentric human leukocyte antigen (HLA) study of 87 anti-IgLON5 patients revealed a stronger association with HLA-DQ than HLA-DR. Specifically, we identified a predisposing rank-wise association with HLA-DQA1*01:05∼DQB1*05:01, HLA-DQA1*01:01∼DQB1*05:01 and HLA-DQA1*01:04∼DQB1*05:03 in 85% of patients. HLA sequences and binding cores for these three DQ heterodimers were similar, unlike those of linked DRB1 alleles, supporting a causal link to HLA-DQ. This association was further reflected in an increasingly later age of onset across each genotype group, with a delay of up to 11 years, while HLA-DQ-dosage dependent effects were also suggested by reduced risk in the presence of non-predisposing DQ1 alleles. The functional relevance of the observed HLA-DQ molecules was studied with competition binding assays. These proof-of-concept experiments revealed preferential binding of IgLON5 in a post-translationally modified, but not native, state to all three risk-associated HLA-DQ receptors. Further, a deamidated peptide from the Ig2-domain of IgLON5 activated T cells in two patients, compared with one control carrying HLA-DQA1*01:05∼DQB1*05:01. Taken together, these data support a HLA-DQ-mediated T-cell response to IgLON5 as a potentially key step in the initiation of autoimmunity in this disease.
Significant Reduction in Bone Density as Measured by Hounsfield Units in Patients with Ankylosing Spondylitis or Diffuse Idiopathic Skeletal Hyperostosis
Swart, Alexander , Hamouda, Abdelrahman M. , Pennington, Zach , Lakomkin, Nikita , Mikula, Anthony L. , Subramaniam, Thirusivapragasam , Sebastian, Arjun S. , Freedman, Brett A. , Fogelson, Jeremy L. , Elder, Benjamin D. , Hamouda, Abdelrahman , Shafi, Mahnoor , Pennington, Zach , Martini, Michael L. , Nassr, Ahmad

Journal of Clinical Medicine | March 1, 2024 | Volume: 13 | Issue: 5 | Pages: 1430

10.3390/jcm13051430 | PMID 38592686 Get It

Background: Multisegmental pathologic autofusion occurs in patients with ankylosing spondylitis (AS) and diffuse idiopathic skeletal hyperostosis (DISH). It may lead to reduced vertebral bone density due to stress shielding. Methods: This study aimed to determine the effects of autofusion on bone density by measuring Hounsfield units (HU) in the mobile and immobile spinal segments of patients with AS and DISH treated at a tertiary care center. The mean HU was calculated for five distinct regions—cranial adjacent mobile segment, cranial fused segment, mid-construct fused segment, caudal fused segment, and caudal adjacent mobile segment. Means for each region were compared using paired-sample t-tests. Multivariable regression was used to determine independent predictors of mid-fused segment HUs. Results: One hundred patients were included (mean age 76 ± 11 years, 74% male). The mean HU for the mid-construct fused segment (100, 95% CI [86, 113]) was significantly lower than both cranial and caudal fused segments (174 and 108, respectively; both p < 0.001), and cranial and caudal adjacent mobile segments (195 and 115, respectively; both p < 0.001). Multivariable regression showed the mid-construct HUs were predicted by history of smoking (−30 HU, p = 0.009). Conclusions: HUs were significantly reduced in the middle of long-segment autofusion, which was consistent with stress shielding. Such shielding may contribute to the diminution of vertebral bone integrity in AS/DISH patients and potentially increased fracture risk.
Management of Adverse Events Associated with Pomalidomide-Based Combinations in Patients with Relapsed/Refractory Multiple Myeloma
Khouri, Jack , Catamero, Donna, Maples, Kathryn T. , Maples, Kathryn , Nadeem, Omar , Ailawadhi, Sikander , Williams, Louis S. , Berdeja, Jesús G.

Cancers | March 1, 2024 | Volume: 16 | Issue: 5 | Pages: 1023

10.3390/cancers16051023 | PMID 38473381 Get It

Multi-agent regimens incorporating immunomodulatory (IMiD®) agents such as thalidomide, lenalidomide, and pomalidomide have become the preferred standard of care for the treatment of patients with multiple myeloma (MM), resulting in improved survival outcomes. Currently, there are three IMiD agents approved for the treatment of MM: thalidomide, lenalidomide, and pomalidomide. Lenalidomide is commonly used to treat patients with newly diagnosed MM and as maintenance therapy following stem cell transplant or after disease relapse. Pomalidomide, the focus of this review, is approved in patients with relapsed/refractory MM (RRMM). Despite survival benefits, IMiD agents each have different safety profiles requiring consideration both prior to starting therapy and during treatment. Adverse event (AE) management is essential, not only to ensure treatment adherence and thus ensure optimal efficacy but also to maintain patient quality of life. Here, we discuss AEs associated with pomalidomide and present five clinically relevant hypothetical case studies in patients with RRMM to provide scenario-driven guidance regarding treatment selection and AE prevention and management in the clinical setting. Lastly, as new treatment approaches continue to be explored in MM, we also discuss novel cereblon E3 ligase modulator (CELMoD™) agents including iberdomide (CC-220) and mezigdomide (CC-92480).
Differences in outcome between left-sided and right-sided mechanical thrombectomy for acute ischemic stroke: A systematic review and meta-analysis
Ramzan, Abdullah , Ghozy, Sherief , Bilgin, Cem , Kadirvel, Ramanathan , Kallmes, David F. , Kadirvel, Ram , Kallmes, David F , Ghozy, Sherief , Bilgin, Cem , Rabinstein, Alejandro A.

Interventional Neuroradiology | March 1, 2024 | Volume: 32 | Issue: 4 | Pages: 1594-1600

10.1177/15910199241236329 | PMID 38425287 Get It

Background Mechanical thrombectomy (MT) is a safe and effective treatment option for acute ischemic stroke due to large vessel occlusion. To investigate differences in outcomes between patients receiving left-sided and right-sided MT, we performed a systematic review and meta-analysis. Methods A systematic literature review was performed using Embase, PubMed, Scopus, and Web of Science databases. Additional literature was searched for manually. Studies reporting safety and efficacy metrics for MT were included. Data regarding the modified Rankin scale (mRS), thrombolysis in cerebral infarction (TICI), symptomatic intracranial hemorrhage (sICH), and 90-day mortality were included. A random-effects model was used to calculate pooled odds ratios (ORs), mean differences (MDs), and 95% confidence intervals (CIs). Results The literature search yielded 13 reports consisting of 19 studies ranging from 98 to 5590 patients. Patients presenting with left-sided stroke had a National Institutes of health stroke scale score 2.89 greater than patients presenting with right-sided stroke (MD = 2.89; 95% CI = 2.09–3.68; P -value < 0.001). There were no differences between left-sided and right-sided MT patients for mRS 0–2 (OR = 0.94; 95% CI = 0.85–1.04; P -value = 0.224), TICI 2b–3 (OR = 1.05; 95% CI = 0.88–1.25; P -value = 0.598), sICH (OR = 0.83; 95% CI = 0.61–1.14; P -value = 0.255), or 90-day mortality (OR = 1.06; 95% CI = 0.84–1.33; P -value = 0.610). Conclusions There does not appear to be a difference in outcomes for patients undergoing left-sided or right-sided thrombectomy.
Assessing Discomfort in American Adult Intensive Care Patients
Gunnels, Marshall S., Reisdorf, Emily M., Mandrekar, Jay , Chlan, Linda L.

American Journal of Critical Care | March 1, 2024 | Volume: 33 | Issue: 2 | Pages: 126-132

10.4037/ajcc2024362 | PMID 38424019 Get It

Background While in the intensive care unit, critically ill patients experience a myriad of distressing symptoms and stimuli leading to discomfort, a negative emotional and/ or physical state that arises in response to noxious stimuli. Appropriate management of these symptoms requires a distinct assessment of discomfort-causing experiences. Objectives To assess patient-reported discomfort among critically ill patients with the English-language version of the Inconforts des Patients de REAnimation questionnaire, and to explore relationships between demographic and clinical characteristics and overall discomfort score on this instrument. Methods This study had a cross-sectional, descriptive, single-cohort design. The convenience sample consisted of alert and oriented patients aged 18 years or older who had been admitted to intensive care units at a Midwestern tertiary referral hospital and were invited to participate. An 18-item questionnaire on physiological and psychological stimuli inducing discomfort was administered once. Each item was scored from 0 to 10, with the total possible discomfort score ranging from 0 to 100. Descriptive statistics were used to analyze participants’ demographic and clinical characteristics and questionnaire responses. Results A total of 180 patients were enrolled. The mean (SD) overall discomfort score was 32.9 (23.6). The greatest sources of discomfort were sleep deprivation (mean [SD] score, 4.0 [3.4]), presence of perfusion catheters and tubing (3.4 [2.9]), thirst (3.0 [3.3]), and pain (3.0 [3.0]). Conclusions Intensive care unit patients in this study reported mild to moderate discomfort. Additional research is needed to design and test interventions based on assessment of specific discomfort-promoting stimuli to provide effective symptom management.
Patient experiences with prenatal cell‐free DNA screening in a safety net setting
Riggan, Kirsten A. , Barwise, Amelia , Yap, Jane Q. , Condon, Niamh, Allyse, Megan , Allyse, Megan A , Barwise, Amelia K , Riggan, Kirsten A , Yap, Jane Q

Prenatal Diagnosis | March 1, 2024 | Volume: 44 | Issue: 4 | Pages: 409-417

10.1002/pd.6541 | PMID 38423995 Get It

AbstractObjectivesThirty‐five states, including Florida, now cover cell‐free DNA (cfDNA) screening of fetuses for all pregnant patients enrolled in state public insurance programs. We interviewed Black and Hispanic obstetric patients at a safety net clinic in Florida shortly after the state rolled out cfDNA as a first‐tier screening method for publicly insured patients.MethodsBlack and Hispanic patients receiving prenatal care from a prenatal or maternal fetal medicine clinic at a federally qualified health center in Jacksonville, FL were invited to participate in a qualitative interview in English or Spanish to explore experiences and perceptions of prenatal cfDNA screening. Participants were recruited following their first prenatal visit when cfDNA is typically introduced. Interview transcripts were qualitatively analyzed for iterative themes based on principles of grounded theory.ResultsOne hundred Black and Hispanic patients (n = 51 non‐Hispanic Black, n = 43 Hispanic, n = 3 Hispanic Black, n = 3 Not Reported/Other) completed an interview. Participants described minimal opportunity for pre‐screening counseling and limited health literacy about cfDNA or its uses. Some believed that cfDNA could positively impact pregnancy health. Many were unsure if they had received cfDNA even though they were aware of the information provided by it. Most participants expressed an interest in cfDNA as a means for early detection of fetal sex and as an additional indication of general fetal health.ConclusionsPatient experiences indicate limited informed consent and decision‐making for cfDNA, discordant with professional guidelines on pre‐screen counseling. Our findings suggest that there should be additional investment in implementing cfDNA in safety net settings to ensure that patients and providers receive the support necessary for effective patient counseling and follow‐on care for the ethical implementation of cfDNA.
Metal artifact reduction sequence-MRI abnormalities in asymptomatic patients with dual-mobility hip prostheses
Chung, Brian , Liu, Kevin C. , Chen, Xiao T. , Lovro, Luke R. , Kistler, Natalie M. , Longjohn, Donald B. , Oakes, Daniel A. , Lieberman, Jay R. , Lovro, Luke R , Heckmann, Nathanael D. , White, Eric A. , Christ, Alexander B.

The Bone & Joint Journal | March 1, 2024 | Volume: 106-B | Issue: 3 Supple A | Pages: 89-96

10.1302/0301-620x.106b3.bjj-2023-0643.r1 | PMID 38423076 Get It

AimsModular dual-mobility (DM) articulations are increasingly used during total hip arthroplasty (THA). However, concerns remain regarding the metal liner modularity. This study aims to correlate metal artifact reduction sequence (MARS)-MRI abnormalities with serum metal ion levels in patients with DM articulations.MethodsA total of 45 patients (50 hips) with a modular DM articulation were included with mean follow-up of 3.7 years (SD 1.2). Enrolled patients with an asymptomatic, primary THA and DM articulation with over two years’ follow-up underwent MARS-MRI. Each patient had serum cobalt, chromium, and titanium levels drawn. Patient satisfaction, Oxford Hip Score, and Forgotten Joint Score-12 (FJS-12) were collected. Each MARS-MRI was independently reviewed by fellowship-trained musculoskeletal radiologists blinded to serum ion levels.ResultsOverall, two patients (4.4%) had abnormal periprosthetic fluid collections on MARS-MRI with cobalt levels > 3.0 μg/l. Four patients (8.9%) had MARS-MRI findings consistent with greater trochanteric bursitis, all with cobalt levels < 1.0 μg/l. A seventh patient had a periprosthetic fluid collection with normal ion levels. Of the 38 patients without MARS-MRI abnormalities, 37 (97.4%) had cobalt levels < 1.0 μg/l, while one (2.6%) had a cobalt level of 1.4 μg/l. One patient (2.2%) had a chromium level > 3.0 μg/l and a periprosthetic fluid collection. Of the 41 patients with titanium levels, five (12.2%) had titanium levels > 5.0 μg/l without associated MARS-MRI abnormalities.ConclusionPeriprosthetic fluid collections associated with elevated serum cobalt levels in patients with asymptomatic DM articulations occur infrequently (4.4%), but further assessment is necessary due to implant heterogeneity.Cite this article: Bone Joint J 2024;106-B(3 Supple A):89–96.